Evaluation of 5-s-cysteinyldopa as a marker of melanoma progression: 10 years' experience

K. Wakamatsu, T. Kageshita, M. Furue, N. Hatta, Y. Kiyohara, J. Nakayama, T. Ono, T. Saida, M. Takata, T. Tsuchida, H. Uhara, A. Yamamoto, N. Yamazaki, A. Naito, S. Ito

Research output: Contribution to journalArticlepeer-review

62 Citations (Scopus)


5-S-Cysteinyldopa (5-S-CD) has been used as a biochemical marker of melanoma progression. In this study, we measured serum levels of 5-S-CD in 2648 samples taken from 218 patients in order to evaluate the usefulness of this parameter in following melanoma progression and prognosis. 5-S-CD levels were significantly elevated above the upper limit of the normal range (10 nmol/l) in stage IV melanoma patients. The sensitivity of elevated serum 5-S-CD levels in detecting distant metastasis was 73%, while the specificity was 98% and the positive predictive value 94%. The sensitivity was improved to 77% when cases of amelanotic melanoma were excluded. Patients without metastases had elevated 5-S-CD values in 5% of the 1480 serum samples. Changes in serum 5-S-CD levels were followed during disease progression until the end stage in 49 patients. In 33% of the patients, elevation of serum 5-S-CD levels preceded clinical detection of visceral metastases, and in 37% elevation of 5-S-CD levels occurred at the same time as visceral metastasis. Patients with elevated 5-S-CD levels before or after surgical treatment had significantly shorter survival times than those with normal levels. These results show that the level of 5-S-CD in the serum is a sensitive and specific marker in predicting distant metastases. Elevated serum levels of 5-S-CD, before or after surgical treatment, is associated with a poor prognosis.

Original languageEnglish
Pages (from-to)245-253
Number of pages9
JournalMelanoma Research
Issue number3
Publication statusPublished - 2002

All Science Journal Classification (ASJC) codes

  • Oncology
  • Dermatology
  • Cancer Research


Dive into the research topics of 'Evaluation of 5-s-cysteinyldopa as a marker of melanoma progression: 10 years' experience'. Together they form a unique fingerprint.

Cite this